Is The European Equity Fund, Inc. (EEA) a Buy, Sell, or Hold?
NYSE : EEA
The European Equity Fund, Inc. — News
$10.93 USD
$0.0 (0.0%)
- Volume
- 10.86K
- Average Volume
- 43.92K
- Market Capitalization
- $73.23M
- P/E Ratio
- 4.03
- Dividend Yield
- 8.86%
- Price Target
- Year High
- $11.43
- Year Low
- $9.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.17
| Source | Headline |
|---|---|
|
The European Equity Fund, Inc. Announces Results of the Fund's Annual Meeting of Stockholders
NEW YORK--(BUSINESS WIRE)--The European Equity Fund, Inc. (NYSE: EEA) (the “Fund”) announced today the results of its Annual Meeting of Stockholders held on June 30, 2026. Both of the two Class III Directors nominated by the Board of Directors, Mr. Bernhard Koepp and Dr. Wolfgang Leoni, were elected to serve a term of one year and until his respective successor is elected and qualifies. Stockholders also ratified the appointment of Ernst & Young LLP as the independent auditors for the Fund. businesswire.com - 2026-06-30 14:48:00 |
|
BitGo Singapore and dtcpay Partner to Advance Secure Digital Asset Infrastructure Across Global Markets
BitGo Singapore Pte. Ltd. (âBitGo Singaporeâ), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (âBitGoâ), the digital asset infrastructure company, a gurufocus.com - 2026-06-16 20:00:00 |
|
XPENG Reports Q1 2026 Results: Gross Margin Sustains High Level of 20.6%, Accelerating Physical AI Mass Production, Commercialization and Globalization
XPENG Reports Q1 2026 Results: Gross Margin Sustains High Level of 20.6%, Accelerating Physical AI Mass Production, Commercialization and Globa gurufocus.com - 2026-05-28 11:00:00 |
|
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1--1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi (seladelpar) was associated with high and sustai gurufocus.com - 2026-05-27 03:00:00 |
|
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex (bulevir gurufocus.com - 2026-05-22 14:00:00 |
|
The European Equity Fund, Inc. and The New Germany Fund, Inc. Declare Distributions
NEW YORK--(BUSINESS WIRE)--The European Equity Fund, Inc. (NYSE: EEA) and The New Germany Fund, Inc. (NYSE: GF) (each, a “Fund,” and collectively, the “Funds”) each announced today that its Board of Directors declared the distributions set forth below. GF's and EEA's total distributions will be paid in stock except that any stockholder of record as of May 26, 2026, may elect to receive such distribution in cash. Details for each Fund's distributions are as follows: Declaration- 05/11/2026 Ex-Da. businesswire.com - 2026-05-11 16:15:00 |
|
The European Equity Fund, Inc. Announces Annual Meeting of Stockholders
NEW YORK--(BUSINESS WIRE)--The European Equity Fund, Inc. (NYSE: EEA) (the “Fund”) announced today that the Annual Meeting of Stockholders for the Fund will be held at 1:00 p.m., Eastern time on June 30, 2026 at the offices of DWS Investment Management Americas, Inc., 875 Third Avenue, New York, New York 10022. Holders of shares of common stock of record of the Fund at the close of business on May 15, 2026 are entitled to vote at the meeting and any postponements or adjournments thereof. At the. businesswire.com - 2026-04-22 16:15:00 |
